AV
$19.20
+0.08
(+0.42%)
As of Oct 22, 2026, 9:32 PM EDT · cached
Price history
Arrivent Biopharma Inc (AVBP) is trading up at $19.20 (+0.42%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: January 26, 2024 · $18.00 offering · NASDAQ · View IPO details →
Arrivent Biopharma Inc net income history (FY2023–FY2025)
Net income
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Operating income | −$74.6M | −$94.3M | −$177.5M |
| Net income | −$69.3M | −$80.5M | −$166.3M |
| EPS (diluted) | −$32.38 | −$2.56 | −$4.32 |
| Balance sheet | |||
| Cash and equivalents | $150.4M | $74.3M | $45.5M |
| Total assets | $163.1M | $274.9M | $333.2M |
| Total liabilities | $11.8M | $17.3M | $25.9M |
| Shareholders' equity | −$153.2M | $257.7M | $307.2M |
| Cash flow | |||
| Operating cash flow | −$55.8M | −$70.2M | −$160.6M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$24.2M | −$23.7M | −$66.8M | −$33.6M | −$38.3M | −$38.8M | −$46.1M | −$52.7M |
| Net income | −$20.6M | −$20.6M | −$64.4M | −$31.4M | −$35.0M | −$35.5M | −$43.3M | −$49.9M |
| EPS (diluted) | −$0.61 | −$0.60 | −$1.90 | −$0.90 | −$0.83 | −$0.69 | −$0.96 | −$1.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $282.9M | $74.3M | $49.9M | $112.8M | $112.7M | $45.5M | $62.1M | $154.7M |
| Total assets | $292.7M | $274.9M | $215.5M | $269.5M | $326.6M | $333.2M | $349.3M | $394.7M |
| Total liabilities | $15.2M | $17.3M | $13.0M | $19.6M | $21.6M | $25.9M | $25.3M | $27.9M |
| Shareholders' equity | $277.5M | $257.7M | $202.5M | $249.9M | $305.0M | $307.2M | $324.0M | $366.8M |
| Cash flow | ||||||||
| Operating cash flow | −$16.3M | −$16.2M | −$68.0M | −$26.1M | −$35.8M | −$30.7M | −$41.9M | −$39.6M |
From Arrivent Biopharma Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Arrivent Biopharma Inc
- Headquarters
- Newtown Square, Pennsylvania From SEC filings, Oct 2026
Recent News (3)
-
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer NEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of inn…
-
ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential securitie…
-
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002 NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of inn…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International